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NeuroOncology planning. Tumor diagnosis, classification, and grading is established by biopsy or excision, which is associated with considerable risk, including death, especially in central areas of the brain. 6 In addition, diagnosis from biopsy sampling or subtotal resection is potentially limited by the sample not being representative, leading to understaging of tumor grade 7 ; in turn, this may mislead treatment planning toward a more conservative strategy. Furthermore, patients who are inoperable or unwilling to undergo surgery, or in whom tumors are located in eloquent areas, might not be suitable for surgical intervention even though they qualify for adjuvant therapy, including chemotherapy and or radiotherapy.
Thus, there is a strong need for alternative methods for grading brain tumors preoperatively with imaging as a reasonable alternative even if there is no ideal imaging technique as of today. MRI, which is done routinely in the presurgical workup of patients with brain cancer, is a reasonable candidate for assessment of tumor grade in gliomas. Potential advantages of MR are its ability to non-invasively map the entire tumor and quantify cerebral blood flow (CBF), a marker of angiogenesis and thus of tumor grade. The diagnostic performance of dynamic susceptibility contrast (DSC) perfusion to discriminate between WHO grades II and III is limited 8 ; in addition the technique requires administration of a gadolinium contrast agent with considerable costs; and more importantly, recent evidence of gadolinium deposition in the brain parenchyma has been reported. 9 Arterial spin labeling (ASL) is a completely non-invasive MR imaging method mainly for measurement of CBF. 10, 11 The ASL technique is based on magnetic labeling of inflowing protons, which subsequently are measured in the brain parenchyma; roughly, CBF maps are acquired by subtraction of background non-labeled tissue. Based on the labeling method, the ASL technique is categorized into continuous ASL (CASL), pulsed ASL (PASL), or pseudocontinuous ASL (pCASL). At present mainly multiphase PASL and 3D pCASL are recommended 12, 13 ; however, there is no consensus regarding the optimal ASL technique for brain tumor evaluation.
A large number of publications have suggested a promising role for ASL for discrimination between high-grade glioma (HGG) and low-grade glioma (LGG), [14] [15] [16] with a strong correlation between DSC-derived CBF and ASL-derived CBF. 17 However, concerns have been raised regarding the interpatient variability in the measurements, 18 as well as the use of divergent parameters and techniques, WHO classification system, and postprocessing schemes. This lack of consensus and guidelines has probably contributed to the reluctance to implement ASL in clinical routine for the management of glioma patients. One meta-analysis concluded that there is a significant difference in blood flow between glioma grades, 19 but the diagnostic performance of ASL to discriminate between tumor grades was not assessed in the study. Therefore the aim of this metaanalysis is to fully assess the diagnostic performance of ASL for differentiation of HGG from LGG, including potential sources of heterogeneity of its diagnostic performance.
Materials and Methods
This meta-analysis was conducted with adherence to the the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines 20 and the Cochrane handbook for systematic reviews of diagnostic test accuracy. 21 The study protocol was prospectively registered in PROSPERO (CRD42017080885).
Search Strategy and Selection Criteria

Literature search
A literature search was performed in the following databases: Medline (OVID), Embase.com (Elsevier), Web of Science Core Collection (Clarivate), and Cochrane Library (Wiley). The MeSH (Medical Subject Headings) terms identified for searching Medline (OVID) were adapted in accordance to the corresponding vocabulary in Embase. Each search concept was also complemented with relevant free-text terms like: brain tumor, astrocytoma, arterial spin labeling, and ASL. The free-text terms were, if appropriate, truncated and/or combined with proximity operators. Conference abstracts were excluded in the search strategy. To include all eligible studies in the search, no language restriction was applied. Databases were searched from inception. All searches were performed by a librarian at the library of Karolinska Institutet in Stockholm, Sweden, in November 2017; the search strategies are available in Supplementary Tables S1-S4 .
Importance of the study
Arterial spin labeling is an MR imaging technique for measurement of CBF without administration of contrast agent. The summary diagnostic performance of ASL to discriminate between glioma grades is unknown, the individual trials assessing this having been limited and hampered by a small number of participants. Accurate diagnosis is important for prognostication, treatment planning, and assessment of treatment response for glioma. Biopsy is highly invasive and carries the risk of undersampling. MRI plays an important role in this regard. This meta-analysis provides evidence that ASL MR imaging has an excellent diagnostic accuracy for differentiation between high-grade and low-grade glioma, in addition to its low cost and non-invasiveness. Its high diagnostic performance was independent of the specific ASL technique used. ASL can be considered for implementation in the routine workup of patients with glioma when gadolinium administration is unwanted or unnecessary.
Study eligibility criteria
We included retrospective and prospective studies that evaluated patients with primary brain tumors, who received diagnoses according to the WHO classification, who were preoperatively examined using ASL, and for whom subsequent neuropathological diagnosis was available. Inclusion criteria were availability of (i) absolute CBF values and normalized CBF values stratified for tumor, and (ii) individual patient data or sensitivity and specificity for discrimination between high-and low-grade glioma. All types of ASL techniques were eligible for inclusion: PASL, pCASL, and CASL were eligible for inclusion. All tumor types as listed in the WHO classification were eligible, since the latest update of the WHO 2016 classification mainly added a strengthened biomolecular classification of tumor types with none or only slight changes in tumor grade classification. 2 Furthermore, only untreated gliomas were eligible for inclusion.
The following exclusion criteria were applied in the meta-analysis: studies with a strict pediatric cohort; studies grouping metastases or meningioma with intracranial tumors, studies reporting on recurrent or treated gliomas only, meningiomas, studies in other languages than English, duplicate or overlapping cohorts, abstracts or editorials. Oligoastrocytomas were excluded if possible from the analysis, since this diagnosis has been removed from the WHO classification 2016 and these tumors are now classified as either oligodendrogliomas or astrocytomas based on biomolecular mutational status. In the case of a duplicate cohort, the largest was included and the overlapping study was excluded from the meta-analysis.
Study selection
After the electronic search was conducted, 2 investigators independently screened and reviewed all titles and abstracts for possible inclusion in the qualitative assessment. Any disagreement between the investigators was solved through discussion with a third investigator, who cast the deciding vote. In addition, the third investigator hand-searched reference lists to identify additional studies.
Quality Assessment
Quality assessment was performed according to the Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) tool, 22 which was adjusted and developed to be used for this particular meta-analysis. Each study was graded according to prespecified criteria in 2 domains. Domain 1 included 4 internal bias items concerning specific quality issues in the included studies: patient selection, index test, reference standard, and flow and timing. Domain 2 consisted of 3 items related to the external validity of the included studies in relation to the specific aim of this meta-analysis: patient selection, index test, and reference standard. Two investigators independently assessed both domains for each study, with any disagreements solved through discussion with a third investigator.
Data Extraction
Data extraction was conducted independently by 2 investigators. The ASL perfusion parameters composed the maximum or mean CBF, relative or equivalent, and the maximum or mean intensity signal (ITS), relative or equivalent, nCBFmeanTI (CBF derived from multi-inversion time [mTI] ASL).
In addition, the following items were extracted: first author name, publication year, town/country of origin, inclusion years, study design, age (mean and standard deviation), WHO classification, specifications for the MR camera used, numbers of channel in head coil, ASL method, flip angle, repetition time, echo time, post labeling delay, acquisition time, region of interest (ROI) technique, reference region, tumor types included.
Any inconsistencies were solved through discussion with a third investigator until consensus.
Main Outcome Measure
The main outcome measure was the diagnostic performance of the ASL parameters for glioma grading. The secondary outcome measure was the diagnostic performance of the different ASL techniques for glioma grading and to assess the heterogeneity of their diagnostic performance.
Data Synthesis
Absolute and relative CBF measures were calculated where possible with mean and SD. For each study, the sensitivity and specificity was calculated with corresponding confidence intervals. The true positive, true negative, false positive, false negative rates and the area under the curve (AUC) were calculated for each study. For studies that only reported individual patient data, receiver operating characteristics curves were calculated optimizing the cutoff for both specificity and sensitivity. The abovementioned calculations were performed independently by 2 investigators and assessed for congruency. Any discrepancies between the investigators were solved through discussion. Mean difference with 95% CI was calculated for HGG and LGG for absolute CBF and regional CBF max with a random effects model.
The sensitivity and specificity heterogeneity between studies was visually assessed by plotting their distribution in a univariable analysis. Exploring heterogeneity by I 2 is not useful for diagnostic meta-analyses that include studies with different thresholds, since this results in high heterogeneity. 23 Instead, we used bivariate meta-regression and subgroup and sensitivity analyses to explore heterogeneity. The following factors were explored in the meta-regression: WHO classification system (year published), MR field strength (in tesla), ASL method (PASL, pCASL, or CASL), and perfusion measure (mean or max CBF [mL/min/100 g], mean or max signal intensity [SI]). We used the funnel plot asymmetry test as described by Egger to explore for potential publication bias and small study effect. 24 
Trial Sequential Analysis
Results in meta-analysis might be caused by random errors rather than reflecting an actual effect. Furthermore, lack of statistical significance might be caused by a lack of statistical power. Random errors are more likely in meta-analysis
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with few studies or if the included studies have small populations. 25 Trial sequential analysis (TSA) is similar to the interim analysis in clinical trials. Using TSA it is possible to calculate the sample size required to demonstrate a difference between LGG and HGG. We calculated the estimated sample size for the meta-analysis to be powered for a one-sided type 1 error of 2.5% using O'Brien-Fleming α-spending function at a power of 90%. We minimized the type 1 error in the TSA by using a highly stringent criterion of 2.5% type 1 error and 90% power. TSA was performed using TSA version 0.9.
Bivariate Analysis
For assessment of the overall diagnostic accuracy of ASL for glioma grading, all studies were included irrespective of the CBF estimate reported, since no threshold was calculated. However, the unit maximum regional CBF, rCBFmax, was used where possible. To obtain summary estimates with 95% CIs, we used a bivariate random effects meta-analysis with a restricted maximum likelihood estimation method to describe the summary receiver operating characteristics (SROC) curve with associated AUC. The following subgroup analyses were performed: studies where maximum and mean rCBF were reported, studies reporting on astrocytomas only, and studies using pulsed, continuous, and pseudocontinuous ASL, respectively. Furthermore, we performed sensitivity analysis by excluding studies with unclear or high risk of bias related to the domain of internal or external validity in QUADAS-2; at least 3 studies with low risk of bias were required to perform sensitivity analysis for any particular item. Statistical analysis was performed in R for Mac v1.1.383 using the mada and metafor package v0.5.8.
Results
Search Hits
The electronic search yielded a total of 640 hits, with 326 remaining after removal of duplicates. All 326 hits were Gr, grade, AC; astrocytoma, DNET, dysembryoplastic neuroepithelial tumor, OA, oligoastrocytoma, GG, ganglioglioma, OD, oligodendroglioma, AOD, (anaplastic OD), AOA, anaplastic OA, GBM, glioblastoma; NA; not available. Table 1 Continued screened for potential inclusion using the criteria described above, and subsequently 48 studies were included in the full-text evaluation. After full-text evaluation, another 34 studies were excluded for the following reasons: absence of sensitivity, specificity, or individual patient data, n = 8; absence of quantitative CBF data n = 17; the paper was not in the English language, n = 4; the material included only glioblastomas, extra-axial tumors or metastases, n = 4. In total, 15 studies comprising 505 patients met the inclusion criteria and were subsequently included in the full metaanalysis (Figure 1 ). [14] [15] [16] [17] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] 
Study Characteristics and Risk of Bias Assessment
A full description of the 15 included studies is presented in Table 1 15 All studies reported on relative values; 9 (60%) used rCBFmax [14] [15] [16] [26] [27] [28] 32, 34, 36 ; of the 4 remaining (27%), 17,28,31,35 1 study reported both rCBFmax and rCBFmean, 28 1 (7%) reported normalized intensity signal (nITSmax), 30 1 nITSmean, 29 and 1 nCBFmeanTI 33 (CBF derived from mTI ASL). In 12 studies (80%), [15] [16] [17] 26, 28, 29, [31] [32] [33] [34] [35] [36] the MR field strength was 3T and in 3 studies (20%), 1.5T. 14, 27, 30 In 13 studies (87%), 14, 16, 17, [26] [27] [28] [29] [30] [31] [32] [33] [34] 36 the risk of bias for patient selection was low, and in 2 (13%) unclear. 15, 35 In all studies the risk of bias related to the reference standard was unclear, since there was no information as to whether the pathologist was blinded for ASL results or not. The time interval between imaging and surgery/biopsy was reported in only 2 (20%) studies. 27, 32, 34 Under the domain of applicability, 
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concerns and external validity related to patient selection: 11 (73%) studies showed low risk bias [14] [15] [16] [17] [26] [27] [28] 31, 34, 36 and 4 (27%) unclear risk of bias pertaining to inclusion of only one tumor type 29, 30, 32, 33 (Table 2 ). The risk of bias concerns were included in the sensitivity analyses. The distribution of sensitivity and specificity was depicted in forest plots and is suggestive of heterogeneity among the included studies related to the specificity for glioma grading among the included studies (Figure 2) .
The bivariate meta-regression assessing potential moderator variables for the primary outcome (diagnostic performance) sensitivity revealed no moderating effect for the following variables; ASL type (PASL, pCASL, or CASL), WHO classification (year published), tesla strength (1.5 or 3), and perfusion parameter (rCBFmax, rCBFmean, nCBFmTI, nITSmax, nITSmean) (P = 0.15-0.65). However, use of the perfusion parameters nITSmax and rCBFmax had a significant effect on the specificity in the bivariate metaregression. The parameter nITSmax was associated with a lower specificity (P = 0.007) compared with rCBFmean/max and nITSmean. The usage of rCBFmax was associated with a higher specificity (P = 0.009) compared with rCBFmean and nITmean/max. The funnel plot assymetry test did not detect any evidence for publication bias (P = 0.53).
Meta-analytic evaluation revealed a mean difference in rCBFmax between HGG and LGG of 3.23 (95% CI: 0.90-5.76, P = 0.007, I 2 = 99%). The mean difference for absolute CBF between HGG and LGG was 45.50 (95% CI: 26.06-64.94, P < 0.001, I 2 = 70%).
Trial sequential analysis revealed that the required sample size to detect a statistical difference between LGG and HGG was n = 187. Hence, this meta-analysis was statistically powered including 505 patients (Figure 1 ).
Diagnostic Performance
In the main analysis, the pooled diagnostic performance for differentiation between high and low grade glioma irrespective of the perfusion measure (CBF or SI) is exemplified by the AUC. The AUC was 0.90 with a summary sensitivity ranging from 0.79 to 0.90, and a summary specificity ranging from 0.72 to 0.87 ( Figure 3 , Table 3 ).
When we only included studies that used rCBFmax to discriminate between LGG and HGG, we found AUC of 0.90, with sensitivity ranging between 0.77 and 0.93 and specificity between 0.76 and 0.91. When we analyzed studies presenting data on mean rCBF, the AUC decreased to 0.78 with a summary sensitivity between 0.63 and 0.83 and summary specificity between 0.60 and 0.84. In the subgroup analyses on studies using the PASL technique, the diagnostic performance for differentiation between LGG and HGG, the AUC was 0.90 with a pooled sensitivity between 0.71 and 0.93, and pooled sensitivity between 0.69 and 0.92. In the subgroup analysis on studies using pCASL, the diagnostic performance AUC was 0.88 with a corresponding summary sensitivity between 0.79 and 0.91, and specificity between 0.65 and 0.87. In order to assess the degree of robustness, we conducted sensitivity analyses by excluding studies with a high or unclear risk of bias in the domain of external validity related to patient selection. This yielded an AUC of 0.88 and a summary sensitivity and specificity between 0. 
Discussion
This study provides evidence that ASL MR imaging has an excellent diagnostic performance of 0.90 with pooled sensitivity of 0.86 and specificity of 0.80 for the differentiation of HGG from LGG. Furthermore, it is non-invasive and does not require a contrast agent. Subgroup analyses showed a similar high diagnostic performance for PASL as for PCASL for HGG detection. We showed that the parameter maximum relative CBF was associated with a higher diagnostic performance compared with the parameter mean relative CBF values, as also suggested by the meta-regression analyses. Sensitivity analyses based on internal and external validity assessment did not alter the results and strengthen the robustness of the conclusion. TSA revealed that the study was adequately powered statistically for detecting a difference between
LGG and HGG. The strengths of this study are related to a broad search strategy, including several databases with a large number of studies, and an adequately powered meta-analysis including a large study cohort with aggregated data from 505 patients. Due to this sample size we were able to pool the data in subgroup analyses. Further, relevant metaregression could be performed to support the findings. In accordance with the current high standards for diagnostic meta-analysis, this study was prospectively registered in PROSPERO 38 and used updated guidelines for reporting meta-analysis 20 and current recommendations for statistical methods in diagnostic meta-analysis. 23 Furthermore, all steps in the meta-analysis were conducted by at least 2 researchers. The electronic search was conducted in wellestablished databases by one experienced librarian, who 
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also searched unpublished gray literature. There were no signs of publication bias in the study. In relation to our study, a recent meta-analysis by Kong and colleagues analyzed CBF in LGG and HGG and found that HGG had a significantly higher CBF compared with LGG, 19 which is in line with our data. However, diagnostic performance evaluation was not assessed in this study, necessitating clarification of the diagnostic value for ASL in identifying HGG.
Dynamic susceptibility MR perfusion, an MR technique utilizing a gadolinium-based contrast agent, has shown an AUC of 0.77 to discriminate between grade II and grade III glioma. 8 However, one strength of the ASL technique compared with other contrast agent-based perfusion techniques is that it does not require a gadolinium contrast agent, which has shown on MR images to accumulate in the brain 9 and in autopsy studies. 39, 40 Furthermore, gadolinium-based contrast agents are associated with the considerable cost of approximately $200 per examination (Swedish retail price, standard dose-male 70 kg). An examination without the need of contrast agent also does not require testing for plasma creatinine and does not involve a risk for gadolinium-related toxicity. 41 Our results in combination with the lesser performance of DSC perfusion can suggest that there is no added value for the purpose of glioma grading using a gadolinium contrast agent. However, most glioma patients require gadolinium to detect contrast enhancing lesions, which although imperfect, is commonly used to describe and characterize tumors, plan surgical resections, and measure Response Assessment in Neuro-Oncology or other standardized response to determine and evaluate treatment. Mean acquisition time for the ASL techniques in the present study was 300 seconds and thus does not prolong the MR scanning time substantially. Proposed drawbacks or limitations of the ASL technique are the signal-to-noise ratio, which is low in the cerebral white matter, 42, 43 as well as aging affecting cerebral perfusion. Based on the data from 505 patients reviewed here, there appears to be little evidence for this claim, and there was only a small difference in the diagnostic performance between PASL and pCASL.
We acknowledge that there are a number of limitations in this study. Firstly, none of the included studies used the current WHO classification system from 2016. 2 One study did report on molecular genetic data; however, there was no separation between metastases and glioma, and therefore this study was excluded. 44 We did try to minimize this 
External validity
Excluding studies with high risk of bias or unclear bias related to patient selection within the domain of external validity *Related to the applicability of the index test in relation to the aim of the meta-analysis. **Related to the applicability of the reference standard in relation to the aim of the meta-analysis. AUC; Area under the receiver operating characteristics curve; QUADAS-2; a revised tool for the quality assessment of diagnostic accuracy studies, PASL; pulsed arterial spin labeling, pCASL; pseudo-continous arterial spin labeling, rCBF; relative cerebral blood flow.
effect by excluding oligoastrocytomas when possible. The new WHO classification does not introduce, per definition, any change regarding glioma grading, therefore the comparison between HGG and LGG is still valid, despite the new classification of tumor subtypes. The included studies used several WHO classification systems; however, the meta-regression analyses did not detect any modulating effect on the outcome. Most of the studies used a 3T scanner; however, this did not seem to alter the outcome. A further limitation is the heterogeneous placement of ROI in the different studies and in the reference regions. Furthermore, there were substantial differences in acquisition and in postprocessing algorithms, if specified at all. In addition, given that grade II and grade III might be a further diagnostic challenge to discriminate between than HGG and LGG, this is a limitation of the study. Moreover, the bivariate meta-regression analyses lack a multivariable implementation that can take several potential moderating variables in the same analysis into consideration. Future studies would need to adopt the WHO classification in order to further assess the role of ASL for glioma grading. ASL MR imaging has an excellent diagnostic performance for differentiation between HGG and LGG. Given the low cost, absence of side effects, and efficacy, ASL MR imaging should be implemented in the routine workup of glioma.
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